| **Table 2: Surgery performed**Placebo (PLA) group and lidocaine (LIDO) group, data as mean ± SD or n (%). |
| --- |
|  |  |  |
|  | **PLA (n = 20)** | **LIDO (n = 20)** |
| Laparotomy | 11 (55) | 12 (60) |
| Laparoscopy | 4 (20) | 5 (25) |
| Both | 5 (25) | 3 (15) |
|  |  |  |
| **Interventions** |  |  |
| Total Mesorectal Excision | 3 (15) | 2 (10) |
| Gastrectomy (total or partial) | 2 (10) | 3 (15) |
| Duodeno-Cephalo-Pancreatectomy | 8 (40) | 4 (20) |
| Abdominoperineal resection | 1 (5) | 1 (5) |
| Surrenalectomy | 1 (5) | 1 (5) |
| Ovarian cancer cytoreductive surgery | 2 (10) | 1 (5) |
| Extensive retroperitoneal lymphadenectomy | 0 | 1 (5) |
| Nephrectomy (total or partial) | 2 (10) | 6 (30) |
| Cystectomy | 1 (5) | 1 (5) |
|  |  |  |
| Duration, skin-to-skin (min) | 232 ± 89 | 228 ± 80 |